6th Mar 2015 07:46
LONDON (Alliance News) - Hutchison China MediTech Ltd said Friday it had finished patient enrolment for its phase II clinical trial of fruquintinib in the treatment of non-small-cell lung cancer.
It expects data from this trial in mid 2015.
The study is a proof-of-concept trial to investigate the efficacy and safety of the compound. Its primary endpoint is progression free survival, with secondary endpoints of disease control rate, overall response rate, overall survival and safety.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed